An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 6, 2012, Pages 1173-1179

  Jacobs, F ^e   Selleslag, D ^a   Aoun, M ^b   Sonet, A ^c   Gadisseur, A ^d  

^a General Hospital St Jan   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN DISEASE; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; CONFUSION; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; DYSURIA; FEMALE; HALLUCINATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INVASIVE ASPERGILLOSIS; KIDNEY DISEASE; LENGTH OF STAY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; SIDE EFFECT; STOMACH PAIN; TREATMENT DURATION; ASPERGILLOSIS; CLINICAL TRIAL; DRUG TOXICITY; MIDDLE AGED; PROSPECTIVE STUDY; SURVIVAL; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84863846189     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1425-5     Document Type: Article

References (26)

1. Maschmeyer G, Haas A, Cornely OA (2007) Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67:1567-1601 (Pubitemid 47267298)
2. Enoch DA, Ludlam HA, Brown NM (2006) Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 55(Pt 7):809-818 (Pubitemid 43974685)
3. Marr KA, Carter RA, Crippa F, Wald A, Corey L (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909-917 (Pubitemid 34229758)
4. Ohmagari N, Raad II, Hachem R, Kontoyiannis DP (2004) Invasive aspergillosis in patients with solid tumors. Cancer 101:2300-2302 (Pubitemid 39458687)
5. Lin SJ, Schranz J, Teutsch SM(2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32:358-366 (Pubitemid 32173620)
6. Kibbler CC, Seaton S, Barnes RA, Gransden WR, Holliman RE, Johnson EM, Perry JD, Sullivan DJ, Wilson JA (2003) Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 54:18-24 (Pubitemid 38002021)
7. European Medicines Agency (EMA) Vfend: EPAR - product information. Available at URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000387/WC500049756.pdf. Accessed 26 September 2011
8. Pfizer Inc. (2010) Vfend (voriconazole) US prescribing information. Last revised December 2010. www.pfizer.com/files/products/uspi-vfend.pdf. Accessed 26 September 2011
9. Alastruey-Izquierdo A, CastelliMV, Cuesta I, Zaragoza O, Monzón A, Mellado E, Rodríguez-Tudela JL (2009) In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect 15(Suppl 5):71-76
10. Walsh TJ, Pappas P,Winston DJ et al (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225-234 (Pubitemid 34438861)
11. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563-571 (Pubitemid 34165316)
12. Perfect JR, Marr KA, Walsh TJ et al (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36:1122-1131 (Pubitemid 36549632)
13. Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415 (Pubitemid 34851833)
14. Böhme A, Ruhnke M, Buchheidt D et al (2009) Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 88:97-110
15. Thursky KA, Playford EG, Seymour JF, Sorrell TC, Ellis DH, Guy SD, Gilroy N, Chu J, Shaw DR (2008) Recommendations for the treatment of established fungal infections. Intern Med J 38:496-520 (Pubitemid 351904422)
16. Walsh TJ, Anaissie EJ, Denning DW et al (2008) Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327-360 (Pubitemid 351265310)
17. Maertens J, Marchetti O, Herbrecht R et al (2010) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant 46:709-718
18. Black N (1999) What observational studies can offer decision makers. Horm Res 51(Suppl 1):44-49 (Pubitemid 29301283)
19. Van Campenhout H, Marbaix S, Derde MP, Annemans L (2008) Voriconazole treatment of invasive aspergillosis: realworld versus health-economic model results. Clin Drug Investig 28:509-521 (Pubitemid 351948054)
20. Ascioglu S, Rex JH, de Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14 (Pubitemid 33152659)
21. Leather H (2005) Economic effects of aspergillosis management in high-risk patients. Manag Care Interface 18:46-52 (Pubitemid 40740525)
22. Patterson TF, Boucher HW, Herbrecht R et al (2005) Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 41:1448-1452 (Pubitemid 41579987)
23. Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, Rijnders BJ (2008) Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 47:1507-1512
24. Alvarez-Lerma F, Nicolás-Arfelis JM, Rodríguez- Borregán JC, Díaz-Regañón J, Sa-Borges M, García-López F, Allepuz-Palau A (2005) Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother 17:417-427 (Pubitemid 41284781)
25. Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342:1878-1886 (Pubitemid 30419053)
26. Herbrecht R, Natarajan-Ame S, Letscher-Bru V, Canuet M (2004) Invasive pulmonary aspergillosis. Semin Respir Crit Care Med 25:191-202 (Pubitemid 38552370)